Industry: Pharmaceuticals, Biotechnology
Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers by introducing proteasome inhibition and thereby disrupting protein turnover in cells, particularly cancer cells, which leads to cell death. Proteolix is developing second generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class. Proteolix is headquartered in South San Francisco. ( www.proteolix.com )
Proteolix , Inc.
230 East Grand Avenue
South San Francisco, California 94080
USA
Tel: (650) 615-7550
Fax: (650) 615-7551